NCT02211872View on ClinicalTrials.gov

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

March 31, 2007

Conditions
Neoplasms
Interventions
DRUG

BI 2536 BS, intravenous

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY